CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Abstract

CSF Aβ reduction is a promising biomarker of neurodegeneration and may predict patients' clinical outcome. Therefore, CSF Aβ should be considered as a potential biomarker of prognostic value.